natgillin/translations-raw huggingface dataset:
The most frequently reported adverse reactions with Levodopa/Carbidopa/Entacapone Orion are dyskinesias occurring in approximately 19% of patients; gastrointestinal symptoms including nausea and diarrhoea occurring in approximately 15% and 12% of patients, respectively; muscle, musculoskeletal and connective tissue pain occurring in approximately 12% of patients; and harmless reddish-brown discolouration of urine (chromaturia) occurring in approximately 10% of patients.
Najčešće prijavljivane nuspojave Levodopa/Carbidopa/Entacapone Oriona su diskinezije koje se javljaju u otprilike 19% bolesnika; gastrointestinalni simptomi uključujući mučninu i proljev javljaju se u otprilike 15%, odnosno 12% bolesnika; bol u mišićima, mišićnokoštana bol i bol vezivnog tkiva javlja se u otprilike 12% bolesnika; te bezopasna crvenkasto-smeđa diskoloracija mokraće (kromaturija) javlja se u otprilike 10% bolesnika.
The most frequently reported adverse reactions with Numient were nausea, occurring in approximately 12% of all patients; dizziness, headache, and dyskinesia, each occurring in approximately 8% of all patients; and insomnia, occurring in approximately 6% of all patients.
Najčešće prijavljivane nuspojave Numienta bile su mučnina, koja se javila u otprilike 12 % svih bolesnika; omaglica, glavobolja i diskinezija, od kojih se svaka javila u otprilike 8 % svih bolesnika; te nesanica koja se javila u otprilike 6 % svih bolesnika.
The most frequently reported adverse reactions, such as gastrointestinal symptoms including abdominal pain, diarrhoea, loose stools, nausea and vomiting, occurred at similar frequencies in vaccine and placebo groups.
Najčešće prijavljivane nuspojave kao što su gastrointestinalni simptomi, uključujući bol u abdomenu, proljev, mekanu stolicu, mučninu i povraćanje, pojavljivale su se sa sličnom učestalošću kod ispitanika koji su dobivali cjepivo i onih na placebu.
The most frequently reported are cleft lip, cardiovascular malformations and neural tube defect.
Najčešće su bili prijavljivani rascjep usne, kardiovaskularne malformacije i defekt neuralne cijevi.
The most frequently reported events were tachycardia (4%) and atrial fibrillation (3%) (see Section 4.4).
Najčešće prijavljeni događaji bili su tahikardija (4%) i fibrilacija atrija (3%) (vidjeti dio 4.4).
The most frequently reported events with abatacept (1-2%) were dizziness, headache, and hypertension.
Najčešće prijavljene nuspojave kod primjene abatacepta (1-2%) bile su omaglica, glavobolja i hipertenzija.
The most frequently reported laboratory abnormalities in paediatric patients receiving REYATAZ oral powder was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4; 16%) and increased amylase (Grade 3-4; 33%), generally of non-pancreatic origin.
Najčešće zabilježeni poremećaj laboratorijskih nalaza u pedijatrijskih bolesnika koji su primali REYTAZ oralni prašak bilo je povišenje ukupnog bilirubina (≥ 2,6 puta iznad gornje granice normale, 3.-4. stupanj; 16%) i povišena vrijednost amilaze (stupanj 3-4; 33%), općenito porijekla koje nije povezano s gušteračom.
The most frequently reported laboratory abnormality in paediatric patients receiving REYATAZ was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4) which occurred in 45% of patients.
Najčešće zabilježeni poremećaj laboratorijskih nalaza u pedijatrijskih bolesnika koji su primali REYATAZ bilo je povišenje ukupnog bilirubina (≥ 2,6 puta iznad gornje granice normale, 3.-4. stupanj), koje je nastalo u 45% bolesnika.
The most frequently reported non-haematological effects were nausea (37 %), diarrhoea (29 %), fatigue (26 %), vomiting (24 %), alopecia (21 %) and anorexia (18 %).
Najčešće prijavljene nehematološke nuspojave bile su mučnina (37%), proljev (29%), umor (26%), povraćanje (24%), alopecija (21%) i anoreksija (18%).
The most frequently reported ocular adverse reactions following injection of Lucentis are: eye pain, ocular hyperaemia, increased intraocular pressure, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye and eye pruritus.
Najučestalije prijavljene okularne nuspojave nakon ubrizgavanja Lucentisa su: bol u oku, hiperemija oka, povišeni intraokularni tlak, vitritis, ablacija staklovine, krvarenje mrežnice, poremećaj vida, plutajući opaciteti u staklovini, krvarenje konjunktive, iritacija oka, osjećaj stranog tijela u oku, pojačano suzenje, blefaritis, suho oko i svrbež oka.
The most frequently reported serious adverse reaction in clinical studies was syncope (0.76%).
Najčešće prijavljivana ozbiljna nuspojava u kliničkim ispitivanjima bila je sinkopa (0,76%).
The most frequently reported serious adverse reaction was immune reconstitution syndrome.
Najčešće prijavljivana ozbiljna nuspojava bio je sindrom imunološke rekonstitucije.
The most frequently reported side effects are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness.
Najčešće su prijavljene nuspojave nazofaringitis, izrazita pospanost, glavobolja, umor i omaglica.
The most frequently reported side effects are:
Najčešće prijavljivane nuspojave:
The most frequently reported side effects in studies with Invega are headache, insomnia (difficulty sleeping), sleepiness, parkinsonism (neurological symptoms including tremor and impaired muscular control), akathisia (restlessness), tachycardia (increased heart rate), dystonia (involuntary muscle contractions), tremor (shaking), upper respiratory tract infection (colds), anxiety, dizziness, increased weight, nausea, agitation, constipation, vomiting, fatigue (tiredness), depression, dyspepsia (heartburn), diarrhoea, dry mouth, toothache, muscle and bone pain, asthenia (weakness), high blood pressure, back pain, prolonged electrocardiogram QT (an alteration of the electrical activity of the heart) and cough.
Najčešće prijavljene nuspojave u ispitivanjima lijeka Invega su glavobolja, nesanica (poteškoće sa spavanjem), pospanost, parkinsoizam (neurološki simptomi uključujući tremor i oštećenu kontrolu mišića), akatizija (nemir), tahikardija (ubrzana frekvencija srca), distonija (nedobrovoljne kontrakcije mišića), tremor (drhtanje), infekcija gornjeg respiratornog trakta (prehlade), tjeskoba, omaglica, povećana tjelesna težina, mučnina, razdražljivost, zatvor, povraćanje, iscrpljenost (umor), depresija, dispepsija (žgaravica), proljev, suha usta, zubobolja, bol u mišićima i kostima, astenija (slabost), visoki krvni tlak, bol u leđima, produljeni QT interval elektrokardiograma (izmjena električne aktivnosti srca) i kašalj.
The most frequently reported symptoms of hypersensitivity include nausea, rash dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, and headache.
Najčešće zabilježeni simptomi preosjetljivosti uključuju mučninu, osip, dispneju, bol u leđima, nelagodu u prsištu (uključujući stezanje u prsištu), urtikariju, artralgiju i glavobolju.
The most frequently reported symptoms of hypersensitivity include nausea, rash, dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, and headache..
Najčešće zabilježeni simptomi preosjetljivosti uključuju mučninu, osip, dispneju, bol u leđima, nelagodu u prsištu (uključujući stezanje u prsištu), urtikariju, artralgiju i glavobolju.
The most frequently reported symptoms were flushing, rash with or without pruritus, chest tightness, back pain, dyspnoea and fever or chills.
Najčešće zabilježeni simptomi bili su crvenilo praćeno osjećajem vrućine, osip sa/bez svrbeža, stezanje u prsištu bol u leđima, dispneja, vrućica ili zimica.
The most frequently used weekly dose was between 3- 5 µg/kg (25th-75th percentile respectively; median 3 µg/kg).
Najčešće primjenjivana tjedna doza bila je između 3 i 5 µg/kg (25. do 75. percentil; medijan 3 µg/kg).
The most important adverse reaction associated with the use of Bronchitol is haemoptysis.
Najvažnija zabilježena nuspojava povezana s primjenom Bronchitola je hemoptiza.
The most important adverse reactions are autoimmunity (ITP, thyroid disorders, nephropathies, cytopenias), IARs, and infections.
Najvažnije nuspojave su autoimunost (imuna trombocitopenična purpura (ITP), poremećaji štitnjače, nefropatije, citopenije), reakcije povezane s infuzijom i infekcije.
The most important parts to note are as follows:
Najvažniji dijelovi koje morate zapamtiti su sljedeći:
The most important serious adverse reactions identified were hepatotoxicity and thrombotic/thromboembolic events.
Najvažnije uočene ozbiljne nuspojave bile su hepatotoksičnost i trombotički/tromboembolijski događaji.
The most important serious adverse reactions were hepatotoxicity and thrombotic/thromboembolic events.
Najvažnije ozbiljne nuspojave bile su hepatotoksičnost i trombotički/tromboembolijski događaji.
The most important serious side effects are kidney failure and impairment; problems with the heart and circulation such as heart failure, blood clots in the arteries leading to stroke or heart attack; bleeding into a tumour in the brain; a syndrome known as ‘posterior reversible encephalopathy syndrome’ characterised by headache, confusion, fits and loss of vision; and liver failure.
Najvažnija ozbiljna nuspojava je zatajenje i oštećenje bubrega; problemi sa srcem i krvotokom poput zatajenja srca, krvnih ugrušaka u arterijama koji rezultiraju moždanim udarom i srčanim udarom; krvarenje u tumor u mozgu; sindrom poznat pod nazivom "posteriorni reverzibilni encefalopatijski sindrom" karakteriziran glavoboljom, konfuzijom, napadajima i gubitkom vida; te zatajenje jetre.
The most important serious side effects are kidney failure and reduced kidney function; problems with the heart and circulation such as heart failure and blood clots in the arteries leading to stroke or heart attack; bleeding in the brain or bleeding of a tumour within the skull; a syndrome known as ‘posterior reversible encephalopathy syndrome’ characterised by headache, confusion, fits and loss of vision; and liver failure.
Najvažnije ozbiljne nuspojave su zatajenje i smanjena funkcija bubrega; problemi sa srcem i krvotokom poput zatajenja srca i krvnih ugrušaka u arterijama koji rezultiraju moždanim ili srčanim udarom; krvarenje u mozgu ili krvarenje tumora unutar lubanje; sindrom poznat pod nazivom „sindrom posteriorne reverzibilne encefalopatije” koji karakteriziraju glavobolja, konfuzija, napadaji i gubitak vida; te zatajenje jetre.
The most important serious side effects seen with other pancreatic enzyme replacement medicines are ‘anaphylactic shock’ and fibrosing colonopathy.
Najvažnije ozbiljne nuspojave zapažene s drugim lijekovima za nadomjesno liječenje enzimima gušterače su "anafilaktički šok" i fibrozirajuća kolonopatija.
The most increased serious adverse events were diarrhoea in patients treated with Vectibix in combination with either FOLFOX or FOLFIRI, and dehydration and pulmonary embolism when patients were treated with Vectibix in combination with FOLFIRI.
Najveći porast učestalosti ozbiljnih štetnih događaja bio je za proljev kod bolesnika liječenih lijekom Vectibix u kombinaciji ili s protokolima FOLFOX ili s FOLFIRI te dehidracija i plućna embolija kod bolesnika liječenih lijekom Vectibix u kombinaciji s protokolom FOLFIRI.
The most likely manifestation of overdose for Rasilamlo would be hypotension, related to the antihypertensive effect of aliskiren and amlodipine.
Najvjerojatnija manifestacija predoziranja Rasilamlom bila bi hipotenzija povezana s antihipertenzivnim učinkom aliskirena i amlodipina.
The most notable unwanted effects reported with efavirenz in combination with other anti-HIV medicines are skin rash and nervous system symptoms.
Najčešće nuspojave povezane s primjenom efavirenza u kombinaciji s drugim lijekovima za liječenje HIV-a su kožni osip i simptomi živčanog sustava.
The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia dizziness, vomiting, increase in serum creatinine, and acute renal failure have also been reported.
Najizraženije manifestacije predoziranja telmisartanom su hipotenzija i tahikardija; također su prijavljeni bradikardija, omaglica, povraćanje, povišene razine serumskog kreatinina i akutno zatajenje bubrega.
The most pronounced increases were observed in patients of low body weight (<30 kg).
Najizrazitija povećanja bila su opažena u bolesnika male tjelesne težine (<30 kg).
The most reported post-marketing ADRs received since the product was authorised for both concentrations were chest pain, flushing, blood pressure increased and decreased, malaise, dyspnoea, nausea, vomiting pyrexia, back pain, headache and chills.
Najčešće prijavljene nuspojave nakon stavljanja lijeka na tržište te otkako su odobrene obje koncentracije lijeka, bile su bol u prsnom košu, iznenadno crvenilo, povišen i snižen krvni tlak, iscrpljenost, zaduha, mučnina, povraćanje, pireksija, bol u leđima, glavobolja i zimica.
The most reported post-marketing ADRs received since the product was authorised for both concentrations were chest pain, flushing, blood pressure increased and decreased, malaise, dyspnoea, nausea, vomiting, pyrexia, back pain, headache and chills.
Najčešće prijavljene nuspojave nakon stavljanja lijeka na tržište te otkako su odobrene obje koncentracije lijeka, bile su bol u prsnom košu, iznenadno crvenilo, povišen i snižen krvni tlak, iscrpljenost, zaduha, mučnina, povraćanje, pireksija, bol u leđima, glavobolja i zimica.
The most serious ADR associated with the use of siltuximab was anaphylactic reaction.
Najozbiljnija nuspojava povezana s primjenom siltuksimaba bila je anafilaktička reakcija.
The most serious ADRs associated with the use of TNF blockers that have been reported for infliximab include HBV reactivation, CHF, serious infections (including sepsis, opportunistic infections and TB), serum sickness (delayed hypersensitivity reactions), haematologic reactions, systemic lupus erythematosus/lupus-like syndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia, Merkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid-like reaction, intestinal or perianal abscess (in Crohn’s disease), and serious infusion reactions (see section 4.4).
Najozbiljnije nuspojave povezane s primjenom blokatora TNF-a, koje su prijavljene za infliksimab, uključuju reaktivaciju hepatitisa B (HBV), kongestivno zatajenje srca, teške infekcije (uključujući sepsu, oportunističke infekcije i tuberkulozu), serumsku bolest (reakcija kasne preosjetljivosti), hematološke reakcije, sistemski eritematozni lupus/sindrom sličan lupusu, demijelinizacijske poremećaje, poremećaje jetre i žuči, limfom, hepatosplenički limfom T-stanica, leukemiju, karcinom Merkelovih stanica, melanom, zloćudne bolesti u pedijatrijskih bolesnika, sarkoidozu/ reakciju nalik na sarkoidozu, intestinalne ili perianalne apscese (kod Crohnove bolesti) i ozbiljne reakcije na infuziju (vidjeti dio 4.4).
The most serious ADRs associated with the use of TNF blockers that have been reported for infliximab include HBV reactivation, CHF, serious infections (including sepsis, opportunistic infections and TB), serum sickness (delayed hypersensitivity reactions), haematologic reactions, systemic lupus erythematosus/lupus-like syndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia, Merkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid-like reaction, intestinal or perianal abscess (in Crohn’s disease), and serious infusion reactions (see section 4.4).
Najozbiljnije nuspojave povezane s primjenom TNF-blokatora, koje su prijavljene za infliksimab, uključuju reaktivaciju hepatitisa B (HBV), kongestivno zatajenje srca, teške infekcije (uključujući sepsu, oportunističke infekcije i tuberkulozu), serumsku bolest (reakcija kasne preosjetljivosti), hematološke reakcije, sistemski eritematozni lupus/sindrom sličan lupusu, demijelinizacijske poremećaje, poremećaje jetre i žuči, limfom, hepatosplenički limfom T-stanica, leukemiju, karcinom Merkelovih stanica, melanom, zloćudne bolesti u pedijatrijskih bolesnika, sarkoidozu/ reakciju nalik na sarkoidozu, intestinalne ili perianalne apscese (kod Crohnove bolesti) i ozbiljne reakcije vezane uz infuziju (vidjeti dio 4.4).
The most serious ADRs associated with the use of TNF blockers that have been reported for Remicade include HBV reactivation, CHF, serious infections (including sepsis, opportunistic infections and TB), serum sickness (delayed hypersensitivity reactions), haematologic reactions, systemic lupus erythematosus/lupus-like syndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia, Merkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid-like reaction, intestinal or perianal abscess (in Crohn’s disease), and serious infusion reactions (see section 4.4).
Najozbiljnije nuspojave povezane s primjenom TNF-blokatora, koje su prijavljene za Remicade, uključuju reaktivaciju hepatitisa B (HBV), kongestivno zatajenje srca, teške infekcije (uključujući sepsu, oportunističke infekcije i tuberkulozu), serumsku bolest (reakcija kasne preosjetljivosti), hematološke reakcije, sistemski eritematozni lupus/sindrom sličan lupusu, demijelinizacijske poremećaje, poremećaje jetre i žuči, limfom, hepatosplenički limfom T-stanica, leukemiju, karcinom Merkelovih stanica, melanom, zloćudne bolesti u pedijatrijskih bolesnika, sarkoidozu/ reakciju nalik na sarkoidozu, intestinalne ili perianalne apscese (kod Crohnove bolesti) i ozbiljne reakcije vezane uz infuziju (vidjeti dio 4.4).
The most serious ADRs that have been reported for golimumab include serious infections (including sepsis, pneumonia, TB, invasive fungal and opportunistic infections), demyelinating disorders, HBV reactivation, CHF, autoimmune processes (lupus-like syndrome), haematologic reactions, serious systemic hypersensitivity (including anaphylactic reaction), vasculitis, lymphoma and leukaemia (see section 4.4).
Najčešće prijavljene ozbiljne nuspojave golimumaba bile su ozbiljne infekcije (uključujući sepsu, pneumoniju, tuberkulozu, invazivne gljivične i oportunističke infekcije), demijelinizirajući poremećaji, reaktivacija virusa hepatitisa B, kongestivno zatajenje srca, autoimuni procesi (sindrom nalik lupusu), hematološke reakcije, ozbiljna sistemska preosjetljivost (uključujući anafilaktičku reakciju), vaskulitis, limfom i leukemiju (vidjeti dio 4.4).
The most serious adverse drug reactions in patients receiving Stivarga are severe liver injury, haemorrhage and gastrointestinal perforation.
Najozbiljnije nuspojave u bolesnika koji su primali lijek Stivarga su teško oštećenje jetre, krvarenje i perforacija u probavnom sustavu.
The most serious adverse effects reported (either of Cyramza alone or in combination with other cancer medicines) included gastrointestinal perforation (a hole that develops in the wall of the gut), severe gastrointestinal haemorrhage (bleeding from the gut) and arterial thromboembolic events (problems caused by blood clots and blockage of the arteries).
Najozbiljnije nuspojave prijavljene (bilo pri monoterapiji lijekom Cyramza ili pri primjeni toga lijeka u kombinaciji s drugim citostaticima) su gastrointestinalna perforacija (rupa koja se razvija u stjenci crijeva), ozbiljno gastrointestinalno krvarenje (krvarenje iz crijeva) i arterijski tromboembolijski poremećaji (problemi uzrokovani krvnim ugrušcima i blokade arterija).
The most serious adverse reaction is hepatotoxicity, primarily as acute hepatocellular toxicity but may also result in cholestatic injury or a mixed pattern of toxicity.
Najozbiljnija nuspojava je hepatotoksičnost, prvenstveno u obliku hepatocelularne toksičnosti, no može doći i do kolestatskog ili mješovitog oštećenja jetre.
The most serious adverse reaction reported in clinical trials with deferiprone is agranulocytosis (neutrophils <0.5x109/l), with an incidence of 1.1% (0.6 cases per 100 patient-years of treatment) (see section 4.4).
Najozbiljnija nuspojava prijavljena u kliničkim ispitivanjima s deferipronom je agranulocitoza (neutrofili <0,5x109/l), s incidencijom od 1,1% (0,6 slučajeva na 100 bolesnika-godina liječenja) (vidjeti dio 4.4).
The most serious adverse reactions are corneal perforation and ulcerative keratitis, which may occur within the 3 months from Holoclar implantation and are related to the corneal epithelial instability, and syncope vasovagal occurring in the first day after surgery due to eye pain.
Najozbiljnije nuspojave su perforacija rožnice i ulcerozni keratitis, koje se mogu javiti unutar 3 mjeseca od implantacije Holoclara i povezane su s nestabilnošću epitela rožnice, te vazovagalna sinkopa koja se može javiti prvi dan nakon operacije zbog bola u oku.
The most serious adverse reactions are respiratory depression (potentially leading to apnoea or respiratory arrest), circulatory depression, hypotension and shock and all patients should be closely monitored for these.
Najozbiljnije nuspojave su respiratorna depresija (koja potencijalno vodi do apneje i respiratornog zastoja), cirkulatorna depresija, hipotenzija i šok, te zbog njihove moguće pojave treba posebno pratiti sve pacijente.
The most serious adverse reactions are respiratory depression (potentially leading to apnoea or respiratory arrest), circulatory depression, hypotension and shock and all patients should be closely monitored for these.
Najozbiljnije nuspojave su respiratorna depresija (koja potencijalno vodi do apneje ili respiratornog zastoja), cirkulatorna depresija, hipotenzija i šok, te zbog njihove moguće pojave treba posebno pratiti sve pacijente.
The most serious adverse reactions associated with sunitinib, some fatal, are renal failure, heart failure, pulmonary embolism, gastrointestinal perforation, and haemorrhages (e.g. respiratory tract, gastrointestinal, tumour, urinary tract, and brain haemorrhages).
Najozbiljnije nuspojave povezane sa sunitinibom od kojih su neke fatalne, su zatajenje bubrega, zatajenje srca, plućna embolija, gastrointestinalna perforacija i krvarenja (npr. krvarenja u dišnom sustavu, probavnom sustavu, tumorska krvarenja te krvarenja u urinarnom traktu i krvarenje u mozgu).
The most serious adverse reactions during treatment were liver aminotransferase abnormalities (see section 4.4).
Najozbiljnije nuspojave tijekom liječenja bile su abnormalnosti aminotransferaza (vidjeti dio 4.4).
The most serious adverse reactions that may occur during blinatumomab treatment include: infections (31.7%), neurologic events (16.4%), neutropenia/febrile neutropenia (15.3%), cytokine release syndrome (0.5%), and tumour lysis syndrome (0.5%).
Najozbiljnije nuspojave do kojih može doći tijekom liječenja blinatumomabom uključuju: infekcije (31,7%), neurološke događaje (16,4%), neutropeniju/febrilnu neutropeniju (15,3%), sindrom otpuštanja citokina (0,5%) i sindrom lize tumora (0,5%).
The most serious adverse reactions that may occur during Kyprolis treatment include: cardiac toxicity, pulmonary toxicities, pulmonary hypertension, dyspnoea, hypertension including hypertensive crises, acute renal failure, tumour lysis syndrome, infusion reactions, thrombocytopenia, hepatic toxicity, PRES and TTP/HUS.
Najozbiljnije nuspojave koje se mogu javiti tijekom primjene lijeka Kyprolis uključuju: kardiološku toksičnost, plućnu toksičnost, plućnu hipertenziju, dispneju, hipertenziju uključujući hipertenzivnu krizu, akutno zatajenje bubrega, sindrom lize tumora, reakcije povezane s infuzijom, trombocitopeniju, hepatotoksičnost, PRES i TTP/HUS.
The most serious adverse reactions were thrombocytopenia and neutropenia (see section 4.4 and ‘Description of selected adverse reactions’ below).
Najozbiljnije nuspojave bile su trombocitopenija i neutropenija (vidjeti dio 4.4 i ‘Opis odabranih nuspojava’ niže).
The most serious effects were thrombocytopenia and neutropenia (low levels of neutrophils, a type of white blood cell that fights infection).
Najozbiljniji učinci su bili oni trombocitopenije i neutropenije (niskih razina neutrofila, tipa bijelih krvnih stanica koje se bore protiv infekcije).